WO1994021812A3 - Hepatitis b escape mutant specific binding molecules - Google Patents

Hepatitis b escape mutant specific binding molecules Download PDF

Info

Publication number
WO1994021812A3
WO1994021812A3 PCT/GB1994/000609 GB9400609W WO9421812A3 WO 1994021812 A3 WO1994021812 A3 WO 1994021812A3 GB 9400609 W GB9400609 W GB 9400609W WO 9421812 A3 WO9421812 A3 WO 9421812A3
Authority
WO
WIPO (PCT)
Prior art keywords
smh
hbs
ecacc
hepatitis
escape mutant
Prior art date
Application number
PCT/GB1994/000609
Other languages
French (fr)
Other versions
WO1994021812A2 (en
Inventor
Jennifer Anne Waters
William Frederick Carman
Howard Christopher Thomas
Original Assignee
Imperial College
Jennifer Anne Waters
William Frederick Carman
Howard Christopher Thomas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939306087A external-priority patent/GB9306087D0/en
Priority claimed from GB939311526A external-priority patent/GB9311526D0/en
Application filed by Imperial College, Jennifer Anne Waters, William Frederick Carman, Howard Christopher Thomas filed Critical Imperial College
Priority to EP94910464A priority Critical patent/EP0689605A1/en
Priority to JP6511507A priority patent/JPH08510635A/en
Priority to AU62870/94A priority patent/AU681636B2/en
Publication of WO1994021812A2 publication Critical patent/WO1994021812A2/en
Publication of WO1994021812A3 publication Critical patent/WO1994021812A3/en
Priority to US08/519,981 priority patent/US6030616A/en
Priority to NO953749A priority patent/NO953749L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Molecules which are capable of specifically binding to a hepatitis B escape mutant antigenic determinant include monoclonal antibodies secreted by the cell line SMH HBs 145/G/R/I (ECACC 92122312), SMH HBs 145/R/I (ECACC 93052626), SMH HBs 145/G/R/II (ECACC 93033109) or SMH HBs 145/R/II (ECACC 93033110) and other specific binding molecules cross-competitive with them. Antibodies secreted by the cell lines SMH HBs 145/G/R/I and SMH HBs 145/G/R/II bind variant (escape mutant) HBsAG and wild type HBsAG. Antibodies secreted by the cell lines SMH HBs 145/R/I and SMH HBs 145/R/II bind variant but not wild type.
PCT/GB1994/000609 1993-03-24 1994-03-24 Hepatitis b escape mutant specific binding molecules WO1994021812A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP94910464A EP0689605A1 (en) 1993-03-24 1994-03-24 Hepatitis b escape mutant specific binding molecules
JP6511507A JPH08510635A (en) 1993-03-24 1994-03-24 Hepatitis B escape mutant specific binding molecule
AU62870/94A AU681636B2 (en) 1993-03-24 1994-03-24 Hepatitis B escape mutant specific binding molecules
US08/519,981 US6030616A (en) 1993-03-24 1995-08-28 Hepatitis B escape mutant specific binding molecules
NO953749A NO953749L (en) 1993-03-24 1995-09-22 Hepatitis B escapemutant-specific binding molecules

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB939306087A GB9306087D0 (en) 1993-03-24 1993-03-24 Specific binding molecules and their uses
GB9306087.9 1993-03-24
GB939311526A GB9311526D0 (en) 1993-06-04 1993-06-04 Specific binding molecules and their uses
GB9311526.9 1993-06-04

Publications (2)

Publication Number Publication Date
WO1994021812A2 WO1994021812A2 (en) 1994-09-29
WO1994021812A3 true WO1994021812A3 (en) 1994-11-10

Family

ID=26302640

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1994/000609 WO1994021812A2 (en) 1993-03-24 1994-03-24 Hepatitis b escape mutant specific binding molecules

Country Status (9)

Country Link
EP (1) EP0689605A1 (en)
JP (1) JPH08510635A (en)
CN (1) CN1121357A (en)
AU (1) AU681636B2 (en)
CA (1) CA2158866A1 (en)
NO (1) NO953749L (en)
NZ (1) NZ262929A (en)
PL (1) PL310699A1 (en)
WO (1) WO1994021812A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9608626D0 (en) * 1996-04-25 1996-07-03 Univ College Of London Hepatitis b monoclonal antibodies
EP0919568A1 (en) 1997-12-01 1999-06-02 Sorin Diagnostics S.r.l. Escape mutant of the surface antigen of hepatitis B virus
AUPP967999A0 (en) 1999-04-09 1999-05-06 North Western Health Care Network Viral variants
PT1766098E (en) 2004-06-07 2014-08-22 Novartis Vaccines & Diagnostic Rabbit monoclonal antibodies to hepatitis b surface antigens and methods of using the same
KR100916992B1 (en) 2004-09-22 2009-09-14 가부시끼가이샤 센단세메이가가꾸겐큐죠 Method of Detecting Hepatitis B Virus s Antigen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991014703A1 (en) * 1990-03-29 1991-10-03 Imperial College Of Science, Technology & Medicine Hepatitis b vaccine
EP0511855A1 (en) * 1991-04-29 1992-11-04 Merck & Co. Inc. HBsAg escape mutant vaccine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991014703A1 (en) * 1990-03-29 1991-10-03 Imperial College Of Science, Technology & Medicine Hepatitis b vaccine
EP0511855A1 (en) * 1991-04-29 1992-11-04 Merck & Co. Inc. HBsAg escape mutant vaccine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
P.G. ASHTON-RICKARDT ET AL.: "Mutants of HBsAg that define same antigenically essential residues in the immunodominant "a" region", JOURNAL OF MEDICAL VIROLOGY, vol. 29, 1989, pages 196 - 203 *
W. F. CARMAN ET AL.: "Vaccine-induced escape mutant of hepatitis B virus", THE LANCET, vol. 336, 11 August 1990 (1990-08-11), pages 325 - 329 *

Also Published As

Publication number Publication date
CN1121357A (en) 1996-04-24
JPH08510635A (en) 1996-11-12
AU6287094A (en) 1994-10-11
NO953749D0 (en) 1995-09-22
CA2158866A1 (en) 1994-09-29
PL310699A1 (en) 1995-12-27
EP0689605A1 (en) 1996-01-03
NZ262929A (en) 1997-08-22
AU681636B2 (en) 1997-09-04
NO953749L (en) 1995-11-22
WO1994021812A2 (en) 1994-09-29

Similar Documents

Publication Publication Date Title
CA2109815A1 (en) Antibody preparation
CA2116764A1 (en) Immunoreactive Hepatitis C Virus Polypeptide Compositions
WO1993000365A3 (en) Hepatitis c virus (hcv) polypeptides
AU642403B2 (en) Method for the use and synthesis of peptides
AU1520895A (en) Purified primate ctla-8 antigens and related reagents
GB9415380D0 (en) Recombinant antibodies specific for tnf-
AU8746582A (en) Hepatitis b virus e type antigen
EP0232921A3 (en) Monoclonal antibodies against hepatitis b virus
AU3459593A (en) Humanised antibody against hepatitis
EP0593290A3 (en) Core antigen protein of hepatitis C virus, and diagnostic method and kit using the same.
CA2080548A1 (en) Monoclonal antibodies to hepatitis c virus
AU2645297A (en) Hepatitis b monoclonal antibodies
AU3330689A (en) Monoclonal antibodies
WO1994021812A3 (en) Hepatitis b escape mutant specific binding molecules
AU2683792A (en) Peptide based hepatitis c virus immunoassays
EP1326895B8 (en) Monoclonal antibodies directed against hepatitis b viruses
EP0613899A3 (en) Cocaine derivative, protein conjugate thereof, monoclonal antibody producing cell line, method for preparing the cell line and monoclonal antibody.
AU7796291A (en) High affinity antibodies to small peptides
EP0600000A4 (en) Hepatitis c assay utilizing recombinant antigens from ns5 region.
EP0685740A3 (en) Separation-free specific binding assays using anti-inhibitor antibodies.
AU1439195A (en) Monoclonal antibodies to hepatitis e virus and methods for using same
AU7862291A (en) Modified antibodies
EP0637631A3 (en) Highly efficient expression of a polypeptide containing a modified preS1 region of the major hepatitis B virus antigen.
ES480624A1 (en) A Purified Cancer Associated Protein
GR3036125T3 (en) Recombinant proteins having the immunoreactivity of Hepatitis B virus e antigens (HBeAg), method for their production and their application in immunoassays and as vaccines.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 94191829.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AU BB BG BR BY CA CN CZ FI GE HU JP KG KP KR KZ LK LV MD MG MN MW NO NZ PL RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR BY CA CN CZ FI GE HU JP KG KP KR KZ LK LV MD MG MN MW NO NZ PL RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 262929

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1994910464

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2158866

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1994910464

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994910464

Country of ref document: EP